Chemspace | aminopiperidin-2-one derivatives

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Ubrogepant (UBRELVY) analogs

26 January 2020

Ubrogepant (UBRELVY) analogs

In December 2019, Ubrogepant (UBRELVY) received approval by the FDA for the treatment of migraine with or without aura. It is an antagonist of calcitonin gene-related peptide receptor. Ubrogepant contains aminopiperidin-2-one moiety in its backbone. We have made a set of Building Blocks, which contain this heterocycle – perfect start for your research!

Ubrogepant (UBRELVY) analogs

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in